Adbiotech Completes KRW 13.3 Billion Capital Increase... Largest Shareholder Changes and Expansion into New Businesses Underway

Adbiotech has completed the payment for its third-party allotment capital increase, accelerating its efforts to restructure its governance and expand into new business areas.

On June 5, the company announced that it had successfully raised a total of 13,261,700,000 won through this capital increase. A total of 7,270,669 new shares were issued, and the listing date for these new shares is scheduled for June 23. The raised funds will be used as operating capital and for other purposes.

The largest shareholder, BK Partners Investment Association No.1, was newly allocated 5,987,774 shares through this capital increase. Including its existing holdings, it now owns a total of 9,395,637 shares, resulting in a post-increase ownership stake of approximately 34.86%.

On the same day, the largest contributor to BK Partners Investment Association No.1 also changed. LNJ Trust Holdings became the new largest contributor, replacing the previous top contributor, Etron. LNJ Trust Holdings secured 100% of the association's shares through a 10.9 billion won new investment and a share transfer agreement for 7.6 billion won worth of existing shares.

The company plans to secure additional funding. Adbiotech announced its decision to issue the 10th series of bearer-type, unsecured convertible bonds (CB) amounting to 3 billion won. The bonds will be allocated to BK Partners Investment Association No.1, with the expected payment date set for August 31. The funds raised will be used for acquiring other companies' securities, expanding new businesses, and securing an operational foundation.

Recently, Adbiotech has been expanding its business focus on bio and digital healthcare, while also reorganizing its organization. The strategy is to maintain its competitiveness in its existing immuno-antibody business while broadening its scope to bio R&D, medical and healthcare, pet care, and digital platform sectors.

A company representative stated, "With the completion of this capital increase, our financial stability and business execution foundation have been strengthened," adding, "We plan to further enhance the competitiveness of our existing immuno-antibody platform business while continuously pursuing new business expansion."

There is an assessment that Adbiotech, through this round of capital raising and the change in the largest contributor, is restructuring its governance and laying the groundwork for a full-fledged expansion centered on bio and digital healthcare businesses.

This content was produced with the assistance of AI translation services.